ImageneBio reports Q2 2026 results as olevaprubart pipeline advances on schedule

ImageneBio reported second-quarter 2026 results on August 5, 2026, alongside updates on its lead asset, olevaprubart (also known as IMG-007), an anti-OX40 receptor antibody. The company said the previously announced protocol amendment to its Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis has been implemented, with the study continuing under the amended design intended to further evaluate the drug's potential.¹ Topline data from the study are still expected in the fourth quarter of 2027.¹

An Independent Data Monitoring Committee reviewed the ADAPTIVE study on July 23, 2026 and recommended it proceed with no changes to protocol or monitoring.¹ As of July 31, 2026, no cases of Kaposi sarcoma had been observed across the olevaprubart program, including in ongoing studies.¹ Separately, a long-term extension study opened for patients who completed one year in the ADAPTIVE trial (NCT07734415), and patients are actively moving into it.¹

In alopecia areata, Imagene remains on track to start a Phase 2 study of olevaprubart in 2026, with initial data expected in 2028, drawing on clinical operations and investigator networks built through the atopic dermatitis program.¹ The company also plans to present two posters on olevaprubart at the 2026 European Academy of Dermatology and Venereology Congress.¹

On the corporate side, Imagene closed a $30 million private placement in April 2026 with participation from new and current investors.¹ In July 2026 the company appointed Yanina Grant-Huerta as Chief Financial Officer and Matt Robbins as General Counsel.¹

On finances, Imagene held $136.2 million in cash, cash equivalents and marketable securities as of June 30, 2026.¹ The company said these resources are expected to fund planned operations into the first quarter of 2028.¹